Literature DB >> 8782748

Caution with use of inhaled nitric oxide.

J B Warren1, T Higenbottam.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8782748     DOI： 10.1016/s0140-6736(05)65068-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS.

Authors:  B H Cuthbertson; P Dellinger; O J Dyar; T E Evans; T Higenbottam; R Latimer; D Payen; S A Stott; N R Webster; J D Young
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

Review 2.  Nitric oxide: biological role and clinical uses.

Authors:  M S Kannan; S Guiang; D E Johnson
Journal:  Indian J Pediatr       Date:  1998 May-Jun       Impact factor: 1.967

3.  Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.

Authors:  M B Hussain; A J Hobbs; R J MacAllister
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 4.  [Iloprost and selective pulmonary vasodilation. Clinical results of intraoperative and postoperative inhalation of iloprost].

Authors:  F Langer; W Wilhelm; H Lausberg; H-J Schäfers
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

5.  Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost.

Authors:  H Olschewski; H A Ghofrani; D Walmrath; B Temmesfeld-Wollbrück; F Grimminger; W Seeger
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

6.  Reduction of NO-induced methemoglobinemia requires extremely high doses of ascorbic acid in vitro.

Authors:  J Dötsch; S Demirakça; A Cryer; J Hänze; P G Kühl; W Rascher
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

Review 7.  The limits of oral therapy in pulmonary arterial hypertension management.

Authors:  Qian-Qian Liu; Zhi-Cheng Jing
Journal:  Ther Clin Risk Manag       Date:  2015-11-23       Impact factor: 2.423
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.